(VIANEWS) – Exelixis (EXEL), USA Compression Partners, LP (USAC), Berkshire Hathaway (BRK-A) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Exelixis (EXEL)
16.2% sales growth and 6.68% return on equity
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Earnings Per Share
As for profitability, Exelixis has a trailing twelve months EPS of $0.5.
PE Ratio
Exelixis has a trailing twelve months price to earnings ratio of 44.38. Meaning, the purchaser of the share is investing $44.38 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.68%.
Sales Growth
Exelixis’s sales growth is 14.8% for the current quarter and 16.2% for the next.
Moving Average
Exelixis’s worth is above its 50-day moving average of $21.24 and way higher than its 200-day moving average of $18.93.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Exelixis’s EBITDA is 3.41.
2. USA Compression Partners, LP (USAC)
15.5% sales growth and 14.3% return on equity
USA Compression Partners, LP provides natural gas compression services. The company offers compression services to oil companies and independent producers, processors, gatherers, and transporters of natural gas and crude oil, as well as operates stations. It primarily focuses on providing natural gas compression services to infrastructure applications, including centralized natural gas gathering systems and processing facilities, as well as gas lift applications for crude oil wells. As of December 31, 2022, the company had 3,716,854 horsepower in its fleet. USA Compression Partners, LP was founded in 1998 and is headquartered in Austin, Texas.
Earnings Per Share
As for profitability, USA Compression Partners, LP has a trailing twelve months EPS of $0.03.
PE Ratio
USA Compression Partners, LP has a trailing twelve months price to earnings ratio of 859.17. Meaning, the purchaser of the share is investing $859.17 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.3%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 20.7%, now sitting on 773.77M for the twelve trailing months.
3. Berkshire Hathaway (BRK-A)
14.6% sales growth and 17.12% return on equity
Berkshire Hathaway Inc., through its subsidiaries, engages in the insurance, freight rail transportation, and utility businesses worldwide. It provides property, casualty, life, accident, and health insurance and reinsurance; and operates railroad systems in North America. The company also generates, transmits, stores, and distributes electricity from natural gas, coal, wind, solar, hydroelectric, nuclear, and geothermal sources; operates natural gas distribution and storage facilities, interstate pipelines, liquefied natural gas facilities, and compressor and meter stations; and holds interest in coal mining assets. In addition, the company manufactures boxed chocolates and other confectionery products; specialty chemicals, metal cutting tools, and components for aerospace and power generation applications; flooring products; insulation, roofing, and engineered products; building and engineered components; paints and coatings; and bricks and masonry products, as well as offers manufactured and site-built home construction, and related lending and financial services. Further, it provides recreational vehicles, apparel and footwear products, jewelry, and custom picture framing products, as well as alkaline batteries; castings, forgings, fasteners/fastener systems, aerostructures, and precision components; and cobalt, nickel, and titanium alloys. Additionally, the company distributes televisions and information; franchises and services quick service restaurants; distributes electronic components; and offers logistics services, grocery and foodservice distribution services, and professional aviation training and shared aircraft ownership programs. It also retails automobiles; furniture, bedding, and accessories; household appliances, electronics, and computers; jewelry, watches, crystal, china, stemware, flatware, gifts, and collectibles; kitchenware; and motorcycle clothing and equipment. The company was incorporated in 1998 and is headquartered in Omaha, Nebraska.
Earnings Per Share
As for profitability, Berkshire Hathaway has a trailing twelve months EPS of $59427.8.
PE Ratio
Berkshire Hathaway has a trailing twelve months price to earnings ratio of 8.82. Meaning, the purchaser of the share is investing $8.82 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.12%.
Previous days news about Berkshire Hathaway(BRK-A)
- According to Zacks on Thursday, 12 October, "In the second quarter, Buffett’s company Berkshire Hathaway established positions in three new stocks: NVR (NVR Quick QuoteNVR – Free Report) , Lennar and D.R. Horton (read: Is It Time to Buy Homebuilding ETFs Following Warren Buffett?)."
- Here's why Berkshire Hathaway B (brk.b) fell more than broader market. According to Zacks on Thursday, 12 October, "Looking at valuation, Berkshire Hathaway B is presently trading at a Forward P/E ratio of 22.03. ", "The investment community will be paying close attention to the earnings performance of Berkshire Hathaway B in its upcoming release. "
4. Align Technology (ALGN)
14% sales growth and 8.68% return on equity
Align Technology, Inc. designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, China, and internationally. It operates in two segments, Clear Aligner; and Imaging Systems and CAD/CAM Services (Systems and Services). The Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign moderate, lite and express packages, and Invisalign go and Invisalign Go Plus; and non-case products that include retention products, Invisalign training, and adjusting tools used by dental professionals during the course of treatment. The Systems and Services segment offers iTero intraoral scanning system, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers. This segment also provides Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan, as well as subscription software, disposables, rentals, leases, and pay per scan services Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.
Earnings Per Share
As for profitability, Align Technology has a trailing twelve months EPS of $4.07.
PE Ratio
Align Technology has a trailing twelve months price to earnings ratio of 65.17. Meaning, the purchaser of the share is investing $65.17 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.68%.
Moving Average
Align Technology’s value is way below its 50-day moving average of $329.29 and way below its 200-day moving average of $316.29.
Previous days news about Align Technology(ALGN)
- According to Zacks on Friday, 13 October, "Some other top-ranked stocks in the broader medical space are Cardinal Health (CAH Quick QuoteCAH – Free Report) , Haemonetics (HAE Quick QuoteHAE – Free Report) and Align Technology (ALGN Quick QuoteALGN – Free Report) , each carrying a Zacks Rank #2. "
- According to Zacks on Thursday, 12 October, "Some better-ranked stocks from the broader medical space that are supposed to report earnings soon are DaVita Inc. (DVA Quick QuoteDVA – Free Report) , Align Technology (ALGN Quick QuoteALGN – Free Report) , and Boston Scientific Corporation (BSX Quick QuoteBSX – Free Report) ."
- According to Zacks on Thursday, 12 October, "Some other top-ranked stocks in the broader medical space are Haemonetics (HAE Quick QuoteHAE – Free Report) , Align Technology (ALGN Quick QuoteALGN – Free Report) and Quanterix (QTRX Quick QuoteQTRX – Free Report) ."
- According to Zacks on Thursday, 12 October, "Some other top-ranked stocks in the broader medical space are DaVita Inc. (DVA Quick QuoteDVA – Free Report) , Quanterix (QTRX Quick QuoteQTRX – Free Report) and Align Technology (ALGN Quick QuoteALGN – Free Report) , each carrying a Zacks Rank #2."
- According to Zacks on Thursday, 12 October, "Some better-ranked stocks in the broader medical space are Cardinal Health (CAH Quick QuoteCAH – Free Report) , Haemonetics (HAE Quick QuoteHAE – Free Report) and Align Technology (ALGN Quick QuoteALGN – Free Report) , each carrying a Zacks Rank #2 (Buy) at present. "
5. The Travelers Companies (TRV)
11.9% sales growth and 9.99% return on equity
The Travelers Companies, Inc., through its subsidiaries, provides a range of commercial and personal property, and casualty insurance products and services to businesses, government units, associations, and individuals in the United States and internationally. It operates through three segments: Business Insurance, Bond & Specialty Insurance, and Personal Insurance. The Business Insurance segment offers workers' compensation, commercial automobile and property, general liability, commercial multi-peril, employers' liability, public and product liability, professional indemnity, marine, aviation, onshore and offshore energy, construction, terrorism, personal accident, and kidnap and ransom insurance products. This segment operates through select accounts, which serve small businesses; commercial accounts that serve mid-sized businesses; national accounts, which serve large companies; and national property and other that serve large and mid-sized customers, commercial trucking industry, and agricultural businesses, as well as markets and distributes its products through brokers, wholesale agents, and program managers. The Bond & Specialty Insurance segment provides surety, fidelity, management and professional liability, and other property and casualty coverages and related risk management services through independent agencies and brokers. The Personal Insurance segment offers property and casualty insurance covering personal risks, primarily automobile and homeowners' insurance to individuals through independent agencies and brokers. The Travelers Companies, Inc. was founded in 1853 and is based in New York, New York.
Earnings Per Share
As for profitability, The Travelers Companies has a trailing twelve months EPS of $9.43.
PE Ratio
The Travelers Companies has a trailing twelve months price to earnings ratio of 17.35. Meaning, the purchaser of the share is investing $17.35 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.99%.
Yearly Top and Bottom Value
The Travelers Companies’s stock is valued at $163.63 at 16:22 EST, way under its 52-week high of $194.51 and above its 52-week low of $159.21.
Sales Growth
The Travelers Companies’s sales growth is 12.3% for the current quarter and 11.9% for the next.
6. Ryman Hospitality Properties (RHP)
8% sales growth and 42.51% return on equity
Ryman Hospitality Properties, Inc. (NYSE: RHP) is a leading lodging and hospitality real estate investment trust that specializes in upscale convention center resorts and country music entertainment experiences. The Company's core holdings* include a network of five of the top 10 largest non-gaming convention center hotels in the United States based on total indoor meeting space. These convention center resorts operate under the Gaylord Hotels brand and are managed by Marriott International. The Company also owns two adjacent ancillary hotels and a small number of attractions managed by Marriott International for a combined total of 10,110 rooms and more than 2.7 million square feet of total indoor and outdoor meeting space in top convention and leisure destinations across the country. The Company's Entertainment segment includes a growing collection of iconic and emerging country music brands, including the Grand Ole Opry; Ryman Auditorium, WSM 650 AM; Ole Red and Circle, a country lifestyle media network the Company owns in a joint-venture with Gray Television. The Company operates its Entertainment segment as part of a taxable REIT subsidiary. * The Company is the sole owner of Gaylord Opryland Resort & Convention Center; Gaylord Palms Resort & Convention Center; Gaylord Texan Resort & Convention Center; and Gaylord National Resort & Convention Center. It is the majority owner and managing member of the joint venture that owns the Gaylord Rockies Resort & Convention Center.
Earnings Per Share
As for profitability, Ryman Hospitality Properties has a trailing twelve months EPS of $4.05.
PE Ratio
Ryman Hospitality Properties has a trailing twelve months price to earnings ratio of 20.9. Meaning, the purchaser of the share is investing $20.9 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 42.51%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 1.3% and positive 2.9% for the next.
Volume
Today’s last reported volume for Ryman Hospitality Properties is 121979 which is 72.68% below its average volume of 446501.
Revenue Growth
Year-on-year quarterly revenue growth grew by 7.6%, now sitting on 2.02B for the twelve trailing months.
7. Manhattan Associates (MANH)
7.6% sales growth and 76.96% return on equity
Manhattan Associates, Inc. develops, sells, deploys, services, and maintains software solutions to manage supply chains, inventory, and omni-channel operations for retailers, wholesalers, manufacturers, logistics providers, and other organizations. The company offers Manhattan SCALE, a portfolio of logistics execution solutions that provide trading partner management, yard management, optimization, warehouse management, and transportation execution services; and Manhattan Active, a set of enterprise and store omni-channel solutions. It also provides inventory optimization and planning solutions; maintenance services comprising customer support services and software enhancements; professional services, such as solutions planning and implementation, and related consulting services; and training and change management services. In addition, the company resells computer hardware, radio frequency terminal networks, radio frequency identification chip readers, bar code printers and scanners, and other peripherals. It offers products through direct sales personnel, as well as through partnership agreements with various organizations. The company operates in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Manhattan Associates, Inc. was founded in 1990 and is headquartered in Atlanta, Georgia.
Earnings Per Share
As for profitability, Manhattan Associates has a trailing twelve months EPS of $2.37.
PE Ratio
Manhattan Associates has a trailing twelve months price to earnings ratio of 83.96. Meaning, the purchaser of the share is investing $83.96 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 76.96%.
Yearly Top and Bottom Value
Manhattan Associates’s stock is valued at $198.98 at 16:22 EST, under its 52-week high of $208.31 and way above its 52-week low of $107.18.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is 15.2% and a drop 18.5% for the next.
Moving Average
Manhattan Associates’s value is above its 50-day moving average of $194.23 and way above its 200-day moving average of $165.43.
